Spikevax: EMA recommendation on booster

25 October 2021 - The EMA’s CHMP has concluded that a booster dose of the COVID-19 vaccine Spikevax (from Moderna) ...

Read more →

Merck and Ridgeback announce initiation of a rolling review by the European Medicines Agency for molnupiravir, an investigational oral anti-viral medicine, for the treatment of COVID-19 in adults

25 October 2021 - If granted marketing authorisation by the European Commission, molnupiravir could be the first oral anti-viral medicine for ...

Read more →

Roche’s Ventana PD-L1 (SP263) assay receives FDA approval as a companion diagnostic to identify certain non-small-cell lung cancer patients eligible for Tecentriq (atezolizumab)

22 October 2021 - The Ventana PD-L1 (SP263) assay helps determine which non-small-cell lung cancer patients may benefit from treatment with ...

Read more →

Alkermes receives FDA fast track designation for nemvaleukin alfa in combination with pembrolizumab for the treatment of platinum-resistant ovarian cancer

26 October 2021 - Second fast track designation for nemvaleukin. ...

Read more →

COVID-19: EMA starts rolling review of molnupiravir

25 October 2021 - EMA’s CHMP has started a rolling review of the oral antiviral medicine molnupiravir (MK 4482; Lagevrio), ...

Read more →

Biden speaks with potential FDA commissioner

25 October 2021 - President Joe Biden recently held a call with Dr. Rob Califf, the former FDA commissioner, who ...

Read more →

European Commission approves Merck’s Keytruda (pembrolizumab) plus chemotherapy as treatment for certain patients with locally recurrent unresectable or metastatic triple negative breast cancer

22 October 2021 - Keytruda is now approved in combination with chemotherapy as first-line treatment for patients with locally recurrent unresectable ...

Read more →

EU decision on Russia's Sputnik V shot 'impossible' this year

21 October 2021 - The EU drug regulator is unlikely to decide whether to approve Russia's Sputnik V coronavirus vaccine until ...

Read more →

Sio Gene Therapies announces granting of FDA fast track designation for investigational AXO-AAV-GM1 (AAV9-GLB1) gene therapy in patients with GM1 gangliosidosis

21 October 2021 - Sio Gene Therapies today announced that the U.S. FDA has granted fast track designation to AXO-AAV-GM1, its ...

Read more →

TGA to consider booster doses as health authorities assure the fully vaccinated that they are protected

23 October 2021 - Australia's medical regulator will look at new data from Pfizer on COVID-19 booster doses on Monday, with ...

Read more →

Oncopeptides withdraws Pepaxto in US, scale down organisation and focus on R&D

22 October 2021 -  Oncopeptides today announces that the company has decided to withdraw Pepaxto (melphalan flufenamide) from the market ...

Read more →

Agenus provides update on balstilimab development

22 October 2021 - Company voluntarily withdraws biologics license application at FDA’s recommendation following full approval of pembrolizumab, which came four months ...

Read more →

FDA approves Roche’s Susvimo, a first of its kind therapeutic approach for neovascular or “wet” age-related macular degeneration

22 October 2021 - Susvimo, previously called Port Delivery System with ranibizumab, is the first neovascular age-related macular degeneration treatment in ...

Read more →

Ultimovacs receives dual FDA fast track designation for UV1 in advanced malignant melanoma

21 October 2021 - UV1 as add-on therapy to checkpoint inhibitors awarded fast track designation. ...

Read more →

FDA issues draft guidance for industry on data standards for drug and biological product submissions containing real world data

21 October 2021 - Today, the U.S. FDA issued a draft guidance for industry titled Data Standards for Drug and Biological ...

Read more →